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Summary
Background 6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 
colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to 
the usual 6 months of treatment.
Methods The SCOT study was an international, randomised, phase 3, non-inferiority trial done at 244 centres. 
Patients aged 18 years or older with high-risk stage II and stage III colorectal cancer underwent central randomisation 
with minimisation for centre, choice of regimen, sex, disease site, N stage, T stage, and the starting dose of 
capecitabine. Patients were assigned (1:1) to receive 3 months or 6 months of adjuvant oxaliplatin-containing 
chemotherapy. The chemotherapy regimens could consist of CAPOX (capecitabine and oxaliplatin) or FOLFOX 
(bolus and infused fluorouracil with oxaliplatin). The regimen was selected before randomisation in accordance with 
choices of the patient and treating physician. The primary study endpoint was disease-free survival and the non-
inferiority margin was a hazard ratio of 1·13. The primary analysis was done in the intention-to-treat population and 
safety was assessed in patients who started study treatment. This trial is registered with ISRCTN, number 
ISRCTN59757862, and follow-up is continuing.
Findings 6088 patients underwent randomisation between March 27, 2008, and Nov 29, 2013. The intended treatment 
was FOLFOX in 1981 patients and CAPOX in 4107 patients. 3044 patients were assigned to 3 month group and 
3044 were assigned to 6 month group. Nine patients in the 3 month group and 14 patients in the 6 month group did 
not consent for their data to be used, leaving 3035 patients in the 3 month group and 3030 patients in the 6 month 
group for the intention-to-treat analyses. At the cutoff date for analysis, there had been 1482 disease-free survival 
events, with 740 in the 3 month group and 742 in the 6 month group. 3 year disease-free survival was 76·7% 
(95% CI 75·1–78·2) for the 3 month group and 77·1% (75·6–78·6) for the 6 month group, giving a hazard ratio of 
1·006 (0·909–1·114, test for non-inferiority p=0·012), significantly below the non-inferiority margin. Peripheral 
neuropathy of grade 2 or worse was more common in the 6 month group (237 [58%] of 409 patients for the subset 
with safety data) than in the 3 month group (103 [25%] of 420) and was long-lasting and associated with worse quality 
of life. 1098 serious adverse events were reported (492 reports in the 3 month group and 606 reports in the 6 month 
group) and 32 treatment-related deaths occurred (16 in each group).
Interpretation In the whole study population, 3 months of oxaliplatin-containing adjuvant chemotherapy was non-
inferior to 6 months of the same therapy for patients with high-risk stage II and stage III colorectal cancer and was 
associated with reduced toxicity and improved quality of life. Despite the fact the study was underpowered, these data 
suggest that a shorter duration leads to similar survival outcomes with better quality of life and thus might represent a 
new standard of care. 
Funding Medical Research Council, Swedish Cancer Society, NETSCC, and Cancer Research UK.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Colorectal cancer is the fourth most common cancer 
worldwide, with 1 360 000 cases occurring annually, 
and is the fifth most common cause of death from 
cancer, causing 694 000 deaths.1 Postoperative adjuvant 
fluoropyrimidine chemotherapy was first shown to 
improve outcomes for patients with stage III colon 
cancer by Moertel and colleagues.2 The addition of 
oxaliplatin to a fluoropyrimidine chemotherapy backbone 
produced additional benefit,3–5 and oxaliplatin-containing 
chemotherapy is a recommended adjuvant treatment for 
stage III colon cancer.6,7
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The major cumulative chronic toxic effect of oxaliplatin-
containing chemotherapy is sensory peripheral neuropathy, 
which can be disabling. This effect is recognised to be 
dependent on dose and duration and can be long-lasting.8,9 
As most patients undergoing adjuvant chemotherapy are 
cured and will survive, long-term, irreversible peripheral 
neuropathy is a significant issue.
The current standard duration of adjuvant chemo 
therapy for colorectal cancer is 6 months. A shorter 
duration of adjuvant chemotherapy would be expected 
to result in less chronic peripheral neuropathy, but it 
has been hitherto unknown to what, if any, extent 
cutting duration would compromise its efficacy. The 
results of one study10 using fluoropyrimidine alone, 
which was not powered for non-inferiority, suggested 
that 3 months of infused fluoropyrimidine was similar 
to 6 months of bolus fluoropyrimidine treatment in 
terms of disease-free survival.10
The SCOT study was designed as a stand-alone 
international phase 3 non-inferiority study to investigate 
whether 3 months of oxaliplatin-based adjuvant chemo-
therapy for colorectal cancer is non-inferior to 6 months 
of treatment with the same regimen. Here we report the 
final efficacy results of disease-free survival and the 
toxicity and quality-of-life (QoL) results.
Methods
Study design and participants
The SCOT study is an international, randomised, non-
blinded, non-inferiority, phase 3 trial comparing 6 months 
versus 3 months of oxaliplatin and fluoropyrimidine 
adjuvant chemotherapy in patients with high-risk stage II 
or stage III colorectal cancer. Patients were recruited from 
244 centres in six countries (the UK, Denmark, Spain, 
Sweden, Australia, and New Zealand).
Patients were eligible if they were aged 18 years or 
older and had undergone a curative resection for stage 
III or high-risk stage II (defined as having one or more 
of T4 disease, tumour obstruction with or without 
perforation of the primary tumour preoperatively, fewer 
than ten lymph nodes harvested, poorly differentiated 
histology, perineural invasion, or extramural venous or 
lymphatic vascular invasion) adenocarcinoma of the 
colon or rectum. Patients were enrolled within 11 weeks 
of surgery and started treatment on their allocated study 
group within 2 weeks of randomisation. Other eligibility 
inclusion requirements included WHO performance 
status 0 or 1, adequate organ function, and life 
expectancy of greater than 5 years with reference to non-
cancer related diseases. Patients had to have a normal 
CT scan of the chest, abdomen, and pelvis before study 
enrolment and carcinoembryonic antigen less than 1·2 
times the local upper limit of normal (ULN) within 
1 week before randomisation. Patients with rectal cancer 
had to have undergone total mesorectal excision surgery 
with negative resection margins (defined as >1 mm 
clearance). Exclusion criteria included chemotherapy 
(except chemotherapy administered with curative intent 
that was completed >5 years ago and from which there 
were no residual complications), previous long-course 
chemo radiotherapy (preoperative short-course radio-
therapy alone was allowed), moderate or severe renal 
impair ment (glomerular filtration rate or creatinine 
clearance <30 mL/min, as calculated with the Cockcroft-
Gault equation), haemoglobin less than 9 g/dL, absolute 
neutrophil count less than 1·5 × 10⁹ cells per L, platelet 
count less than 100 × 10⁹ cells per L, and aspartate 
aminotransferase or alanine aminotransferase greater 
than 2·5 times the ULN. Other exclusion criteria were 
clinically significant cardiovascular disease, pregnancy 
or lactation or being of child-bearing potential and 
not using, or willing to use, medically approved 
contraception (postmenopausal women must have been 
amenorrhoeic for at least 12 months to be considered of 
Research in context
Evidence before this study
6 months of adjuvant oxaliplatin and fluoropyrimidine 
chemotherapy has been an option for patients with high-risk 
stage II and stage III colorectal cancer, as reflected in several 
international guidelines. Only one small study has investigated 
a 3 month duration of fluoropyrimidine adjuvant treatment. 
In view of the cumulative peripheral neuropathy that occurs 
with oxaliplatin, there was a question of whether a shorter 
duration of treatment would reduce toxicity without sacrificing 
efficacy. The SCOT study was designed to test for the 
non-inferiority of 3 months of treatment compared with the 
standard 6 month duration.
Added value of this study
Worldwide, six studies have addressed this research question, of 
which SCOT is the largest. Our results showed the non-inferiority 
of 3 months of adjuvant treatment compared with 6 months of 
treatment for the overall study population. Peripheral 
neuropathy was significantly worse in the 6 month group and 
reducing the treatment duration to 3 months more than halved 
the number of grade 3 or 4 peripheral neuropathy events 
reported. Moreover those patients who were most severely 
affected by peripheral neuropathy also had a significant 
reduction in quality of life.
Implications of all the available evidence
In view of the results of the SCOT study and the meta-analysis 
of all six worldwide studies conducted by the IDEA 
collaboration, 3 months of adjuvant chemotherapy will become 
the new global standard of adjuvant treatment for most 
patients who are suitable for treatment with CAPOX, 
particularly those patients with T1–3, N1 disease.
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non-childbearing potential), previous malignancy other 
than adequately treated in-situ carcinoma of the uterine 
cervix or basal or squamous cell carcinoma of the skin 
(unless there had been a disease-free interval of at least 
5 years), and known or suspected dihydropyrimidine 
dehydrogenase deficiency.
The study was done in accordance with the Declaration 
of Helsinki and Good Clinical Practice guidelines. 
All aspects of the study received ethics approval from the 
National Research Ethics Service or its equivalent in 
the participating countries. This study was approved by 
the West Glasgow Research Ethics Committee (version 1.1 
of the protocol) on Jan 21, 2008, and all subsequent 
amendments approved by the committee, where required 
(REC reference number 07/S0703/136). All participants 
provided written informed consent before enrolment. 
The full study details are available in the trial protocol, 
which is available online. 
Randomisation and masking
By use of a minimisation algorithm incorporating a 
random component, patients were centrally randomly 
assigned (1:1), to receive either 3 months or 6 months of 
treatment. The minimisation factors were centre, choice 
of regimen, sex, disease site (colon vs rectum), N stage 
(X, 0, 1, or 2) and T stage (X, 0, 1, 2, 3, or 4) and, if the 
patient was going to receive the CAPOX (capecitabine 
and oxaliplatin) regimen, the starting dose of capecitabine 
(from Feb 1, 2010).
Initially some participating centres were randomly 
allocated to randomise patients after completion of the 
first 3 months of treatment to either receive a further 
3 months treatment or to stop treatment. This approach 
was stopped because of a poorer randomisation rate 
(ie, fewer patients randomised per month) compared 
with centres that randomised patients before the start 
of treatment.11
Participants were enrolled by authorised clinicians, 
after obtaining patient consent, by contacting the Cancer 
Research UK Clinical Trials Unit in Glasgow, UK, to 
check eligibility and request an allocation. At the end of 
the randomisation process, the computer randomisation 
system allocated every patient a unique identification 
number and determined their treatment duration. 
The study was open-label for patients, clinicians, and 
those doing the data analysis.
Procedures
Patients were assigned to receive oxaliplatin-containing 
adjuvant treatment for either 3 months or 6 months. 
The chemotherapy regimen, which could be FOLFOX 
(bolus and infused fluorouracil with oxaliplatin) or 
CAPOX, was chosen by the physician and patient and 
was not randomised.
For patients receiving FOLFOX, treatment was given 
every 2 weeks with the intention of delivering six cycles 
to patients assigned 3 months of therapy and 12 cycles 
to patients assigned 6 months of therapy. Intravenous 
oxaliplatin 85 mg/m² was given over 2 h on day one 
concurrently with L-folinic acid 175 mg or folinic acid 
(leucovorin) 350 mg. This was followed by an 
intravenous bolus injection of fluorouracil 400 mg/m² 
over 5 min, then a continuous intravenous infusion of 
fluorouracil 2400 mg/m² over 46 h. At the investigator’s 
discretion, patients receiving FOLFOX who were older 
than 70 years could start on the bolus and continuous 
infusion of fluorouracil at 75% of the starting dose, if 
clinically indicated.
For patients receiving CAPOX, treatment was given 
every 3 weeks with an intention of delivering four cycles 
to patients assigned 3 months of therapy and eight cycles 
to patients assigned 6 months of therapy. Intravenous 
oxaliplatin 130 mg/m² was given on day one over 2 h. 
Oral capecitabine 1000 mg/m² was taken twice per day for 
the first 14 days of each cycle. Patients with a creatinine 
clearance of 30–50 mL/min had to start treatment with 
capecitabine at 75% of the full dose. Patients older than 
70 years could be considered for treatment with 
capecitabine at 75% of the full dose, but the decision to 
reduce dose was left to the discretion of the investigator, 
depending on the fitness of the individual patient. If the 
clinician felt that any other patient required a-priori dose 
reduction because of any other comorbidity, that patient 
could be started on a minimum starting dose of oral 
capecitabine 800 mg/m² twice per day. 
Toxicity was assessed by the investigators after each 
cycle of chemotherapy treatment and graded by use 
of National Cancer Institute Common Terminology 
Criteria for Adverse Events (CTCAE) version three. 
If any grade 1 adverse event occurred as a result of 
chemotherapy, treatment was continued at the full 
dose. For all treatment-related adverse events of grade 2 
or worse, treatment was withheld until recovery to 
grade 1, then restarted. For CAPOX, if more than one 
delay or a delay of at least 2 weeks occurred, capecitabine 
and oxaliplatin doses were reduced by 25% and, if 
further delays occurred due to myelotoxicity, further 
dose reductions were allowed at the investigators 
discretion. For FOLFOX, if more than one delay or a 
delay of at least 2 weeks occurred, doses of oxaliplatin 
and infused fluorouracil were maintained, but the 
bolus fluorouracil was omitted and, if further delays 
occurred due to myelotoxicity, the oxaliplatin and 
infusional fluorouracil doses were reduced by 25%. 
Also for FOLFOX, if after the first cycle neutrophils 
were less than 1·0 × 10⁹ cells per L, the bolus fluorouracil 
was omitted and the oxaliplatin and infused fluorouracil 
doses were reduced by 25%. Wherever possible for toxic 
effects, the oxaliplatin dose was reduced rather than 
discontinued. If oxaliplatin was discontinued, the 
fluoropyrimidine was continued if possible. Patients 
were followed up for 8 years with full blood count, urea 
and electrolyte, liver function, and carcinoembryonic 
antigen tested at months 9, 12, 18, 24, and 36, then 
For the trial protocol see 
http://www.crukctuglasgow.org/
media/publications/SCOT_
Protocol_V7_11Feb2016_
withsignature.pdf
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annually. CT of the chest, abdomen, and pelvis was 
done at months 6, 12, 18, 24 and 36.
QoL was assessed with the European Organisation for 
Research and Treatment of Cancer (EORTC) QLQ-C30 
and QLQ-CR29 and EQ-5D-3L (visual analogue scale and 
health index), with UK value sets.12 Neuropathy was 
assessed with the FACT/GOG-Ntx4 questionnaire.
The QoL questionnaires were administered at baseline 
and before each treatment cycle. Additionally, QoL was 
assessed each month in the 3 month group for the first 
3 months after treatment. Subsequent assessments were 
made at months 9 and 12 for the EORTC questionnaires 
and months 9, 12, 18, and 24, then annually for EQ-5D-3L.
Neuropathy assessments with FACT/GOG-Ntx4 were 
initially completed up to 12 months, as were the EORTC 
questionnaires in patients who underwent randomisation 
before Feb 16, 2011, from sites that opted to participate in 
this substudy. An amendment introduced in version 3.0 of 
the protocol on March 20, 2012, extended the requirement 
for the neuropathy questionnaire to be completed for 
patients who completed it at baseline to the follow-up visits 
at months 18 and 24. A further amendment (version 4.0 on 
Dec 20, 2012) extended the requirement for the neuropathy 
questionnaire to be completed to every follow-up visit (to a 
maximum of 8 years) for all new patients and existing 
patients already participating in the substudy. These 
amendments were made as a result of recommendations 
by the independent data monitoring committee.
Outcomes
The primary study endpoint was disease-free survival, 
defined as the time from randomisation (or trial 
registration for those randomised after 3 months of 
therapy) to relapse, development of a new colorectal cancer, 
or death from any cause. Secondary endpoints were overall 
survival, safety, QoL, and cost-effectiveness, which will be 
reported separately. Overall survival was defined as the 
time from randomisation (registration for those 
randomised at 3 months) to death from any cause. 
At selected centres, patients were entered into a 
translational substudy, the TransSCOT study and had 
tissue and blood samples collected.
Statistical analysis
In the MOSAIC trial, 3 year disease-free survival in the 
FOLFOX group was 78% as compared with 73% with 
fluorouracil and leucovorin.3 To conclude non-inferiority 
for the 3 month group, we would wish to be confident 
that at least half of this benefit was retained.
SCOT was designed as a non-inferiority trial aiming to 
reliably determine whether there was less than a 2·5% fall 
in 3 year disease-free survival for patients in the 3 month 
treatment group (from 78% in the 6 month group), which 
corresponds to excluding a hazard ratio (HR) greater than 
1·13 with 90% power at the 2·5% one-sided level of 
significance. Assuming that the study would recruit over a 
period of 5 years with a subsequent minimum follow-up 
of 2 years, this design required 8600 patients to undergo 
randomisation and 2750 events (relapses, deaths, or new 
colorectal cancers) to be observed. To allow for losses to 
follow-up, our target recruitment was 9500 patients.
From the outset, we recognised that reliable conclusions 
based on safety and QoL data would not require 
information on all 9500 patients. For safety outcomes, 
the plan was that 700 patients (350 in each group) would 
be sufficient to detect (with 80% power and two-sided 
significance level of 5%) a halving in the proportion of 
patients with grade 3 or 4 toxic effects from 12% to 6% 
(12% being the rate at which grade 3 or 4 paraesthesia—
the most frequent non-haematological grade 3 or 4 toxic 
effect—occurred in the oxaliplatin group in the MOSAIC 
trial).3 This same sample size would allow small changes 
in global QoL to be detected (assuming a difference of 
magnitude of 7·5313 and a standard deviation of 23·4)14 
with 95% power at the 1% significance level. This more 
stringent level of significance was used to allow for 
multiple testing across the various QoL scales.
We collected information on these toxicity and QoL 
endpoints from all patients recruited until the number 
required was exceeded and the decision to stop was 
endorsed by the independent data monitoring committee 
and trial steering committee. An administrative delay in 
notifying the sites about the need to end the collection of 
detailed toxicity data resulted in data being collected 
from 868 patients. The data monitoring committee had 
access to summary plots of EORTC QoL data, EQ-5D 
health status, and FACT/GOG-Ntx4 neuropathy data by 
study group and study timepoints and following a 
committee meeting on May 28, 2010 (based on 
1047 randomised patients), recommended that the 
collection of QoL and FACT/GOG-Ntx4 data be 
continued because they were concerned that the amount 
of missing data might undermine the comparisons at 
later timepoints if the original sample size estimates 
were used. They also recommended that the collection 
of FACT/GOG-Ntx4 data should be extended beyond 
12 months for new patients and, where possible, for 
patients already on the study. At their next meeting on 
Nov 23, 2010, the data monitoring committee 
recommended that the collection of QoL and 
FACT/GOG-Ntx4 data should stop once 1800 patients 
had been recruited. Delays in the amendment of the 
protocol to implement the collection of the FACT/GOG-
Ntx4 beyond 12 months led to patient recruitment 
beyond this recommendation to ensure sufficient 
numbers of patients at these later timepoints. These 
recommendations were subsequently endorsed by the 
trial steering committee. These extensions to data 
collection were made to compensate for missing data 
and no formal power calculations were made for these 
changes.
The efficacy analyses of disease-free survival and 
overall survival included all randomly assigned patients 
(intention-to-treat population) as far as possible. 
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Kaplan-Meier techniques were used to plot both 
disease-free survival and overall survival. The analysis 
of treatment delivery and safety was based on patients 
who started study treatment.
The comparison of disease-free survival and overall 
survival between the treatment groups was based on a 
Cox regression model incorporating the minimisation 
factors as covariates. The HR associated with the 
treatment groups was derived from this model along 
with the associated 95% CI. The p value for testing the 
null hypothesis that the HR of 3 months versus 6 months 
was greater than or equal to 1·13 was derived from this 
model by comparing the log-likelihood of the fitted 
model with the log-likelihood of a model where the HR 
between the groups is set to 1·13 by use of a likelihood 
ratio test. The proportional hazards assumption implicit 
in these analyses was examined graphically via a 
log-minus log plot of the survival function against log 
time and via a test of the interaction between the 
treatment group and time (logged) obtained from a Cox 
model incorporating an appropriate time-varying 
covariate.
The components of the forest plot (estimated HR 
for the comparison between groups and associated 
95% CI) were derived from a Cox model that included 
separate terms for the effect of duration within each 
category of the relevant stratification factor or other factor 
being examined. The p value for heterogeneity was 
derived from a comparison of the log-likelihoods of a 
model with separate terms for the effect of duration 
within each category with the model with a single overall 
term. The aim of this analysis was to establish whether 
434 included in CTCAE analysis 
916 included in EORTC QLQ-C30/ CR229 analysis 
916 included in EQ-5D analysis
1445 included in GOG NTX4 analysis
6088 entered randomisation
215 registered to study before starting adjuvant
chemotherapy to be randomised at 3 months
5929 registered to study to be randomised before
starting adjuvant chemotherapy
     
3044 assigned to 3 months of treatment
3035 gave consent to use data
16 ineligible* (included in ITT analysis) 
      6 wrong stage
      9 excess delay from surgery to chemotherapy
      1 not R0 resection 
   9 withdrew consent for use of on study data
3030 gave consent to use data
3009 started study treatment 3013 started study treatment
3035 included in ITT analysis 3030 included in ITT analysis
434 included in CTCAE analysis
913 included in EORTC QLQ-C30/CR229 analysis
912 included in EQ-5D analysis
1426 included in GOG NTX4 analysis
11 ineligible* (included in ITT analysis)
      4 wrong stage
      6 excess delay from surgery to chemotherapy
      1 not R0 resection 
14 withdrew consent for use of on study data
26 did not start study treatment†
       1 adverse event
       9 protocol violation or ineligibility
       6 clinical decision
       4 patient decision
       9 other 
       1 reason missing 
17 did not start study treatment†
      3 adverse events 
      5 protocol violation or ineligibility
      5 clinical decision
      4 patient decision
      2 other 
      3 reason missing 
3044 assigned to 6 months of treatment
56 registered patients not randomised at 3 months
       22 stopped treatment before 3 months
6 not fit to receive more than 3 months of
treatment
          1 withdrew consent 
       27 other reasons 
Figure 1: Trial profile
ITT=intention to treat. CTCAE=Common Terminology Criteria for Adverse Events. *Based on retrospective review. †Patients could have more than one reason.
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the impact of treatment duration varied across important 
patient subgroups.
Multiple imputation analysis15 was used to fill in the 
missing data and questionnaires in the QoL and 
neuropathy scales. Five multiple imputation sets were 
produced for each QoL or neuropathy scale and the area 
under the curve (AUC)16 was calculated with the imputed 
data. This was prespecified in the statistical analysis 
plan. This AUC was then adjusted by dividing by the 
follow-up period and subtracting the baseline value for 
each patient to produce a standardised adjusted AUC. 
The standardised adjusted AUC was calculated for the 
five imputed datasets and compared between the 
randomised treatment groups via a generalised linear 
model (with study group as an independent factor and 
study minimisation factors as covariates). The test 
statistics associated with study group from each of the 
five imputations were finally combined to provide an 
overall p value that takes into account the extent of the 
missing data. To allow for the number of scales being 
examined, an adjustment for multiple comparisons 
(separately for the EORTC and EQ-5D questionnaires) 
was made with the sharpened Hochberg procedure.17 
The p value threshold for statistical significance was 5% 
after adjustment. Comparisons of these scales at 
individual timepoints also made use of multiple 
imputation and generalised linear models.
The Mann-Whitney U test was used for the comparison 
of ordered categorical variables for toxicity grade. 
Fisher’s exact test was used to compare the incidence of 
grade 3–5 toxic effects and the odds ratio and associated 
confidence interval for the incidence of grade 3–5 toxicity 
was estimated using logistic regression.
The study data were reviewed by the data monitoring 
committee approximately once per year to assess safety 
and efficacy issues from an ethical viewpoint. 
Conditional power methods18 were used to aid the 
committee in reaching decisions about study 
continuation, but no formal stopping rules were set. 
The conditional power for disease-free survival was 
presented at the fifth (June 26, 2012), sixth (Jan 7, 2013), 
and seventh (Oct 2, 2013) meetings of the data 
monitoring committee. The data monitoring committee 
requested the analysis because of apparent differences 
in disease-free survival curves. The conditional power 
results were discussed by the data monitoring 
committee in the context of the limited follow-up on 
patients and the available survival data. The data 
monitoring committee also had access to interim 
disease-free survival results from an Italian study 
TOSCA (NCT00646607), which was addressing the 
same question and had more mature data at the time. 
The data monitoring committee concluded that no 
action was required taking all information into account.
All statistical analyses were done with SPSS version 22 
and R version 3.1.2. This trial is registered with ISRCTN, 
number ISRCTN59757862, and follow-up is continuing.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All authors had full access to all the 
raw data and the corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Between March 27, 2008, and Nov 29, 2013, 6088 patients 
underwent randomisation (figure 1) at 244 centres, 
3 months of 
treatment 
(n=3044)
6 months of 
treatment 
(n=3044)
Sex
Female 1201 (39%) 1200 (39%)
Male 1843 (61%) 1844 (61%)
Age (years)
Median 65 (58–70) 65 (58–70)
Performance status at randomisation
0 2190 (72%) 2144 (70%)
1 854 (28%) 900 (30%)
Disease site
Colon 2492 (82%) 2495 (82%)
Rectum 552 (18%) 549 (18%)
T stage
0 1 (<1%) 3 (<1%)
1 92 (3%) 95 (3%)
2 284 (9%) 283 (9%)
3 1749 (57%) 1748 (57%)
4 917 (30%) 915 (30%)
X 1 (<1%) 0
N stage
0 559 (18%) 557 (18%)
1 1731 (57%) 1732 (57%)
2 754 (25%) 755 (25%)
Planned treatment
FOLFOX 993 (33%) 988 (32%)
CAPOX 2051 (67%) 2056 (68%)
Starting dose of capecitabine if CAPOX planned
750 mg/m² 348 (19%) 349 (19%)
800 mg/m² 72 (4%) 78 (4%)
1000 mg/m² 1369 (77%) 1370 (76%)
Number of patients with data 
available
1789 1797
High risk stage II
No 2493 (82%) 2499 (82%)
Yes 551 (18%) 545 (18%)
Randomisation timepoint
Baseline 2964 (97%) 2965 (97%)
3 months 80 (3%) 79 (3%)
Data are n (%) or (IQR) unless noted otherwise. 
Table 1: Baseline patient characteristics recorded at randomisation by 
study group
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including 5244 patients at 164 centres in the UK, 
197 patients at 32 centres in Australia, 237 patients at 
19 centres in Spain, 83 patients at 14 centres in Sweden, 
311 patients at ten centres in Denmark, and 16 patients 
at five centres in New Zealand. The study did not meet 
its recruitment target of 9500 patients because accrual 
was not as rapid as originally forecast and recruitment 
needed to stop to allow sufficiently complete follow-up 
on current patients within the available funding. 
By increasing the recruitment period by 6 months and 
extending minimum follow-up to 3 years (88% patients 
were followed up for 3 year disease-free survival by the 
reverse Kaplan-Meier method, allowing for a 2 month 
deviation from the assessment time), 1482 disease-free 
survival events were observed, giving the study 66% 
power rather than the originally planned 90% power for 
rejecting the null hypothesis. Results from previous 
adjuvant studies have shown that most disease-free 
survival events occur within the first 3 years of starting 
treatment.3,19 The analysis time was prespecified in the 
protocol and therefore no bias would be introduced as 
might be the case if we had allowed the timing of the 
analysis to be guided by the data at hand.
The data cutoff for this analysis was Dec 1, 2016. 
The median follow-up time in both groups was 
37 months (IQR 36–49), which we calculated by the 
reverse Kaplan-Meier approach. 787 patients had died at 
the time of analysis.
Figure 2: Disease-free survival (A) and overall survival (B) by study group
HR=hazard ratio.
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The baseline demographics, stage, and site of disease 
for each group were balanced across the trial population 
(table 1). The corresponding information for the patients 
with data on CTCAE-graded adverse events and EQ-5D, 
EORTC QLQ-C30/CR229, and FACT/GOG-Ntx4 are 
shown in the appendix (pp 6–9). Patients were also well 
balanced across the treatment groups within these 
subgroups, with a similar overall distribution of patient 
characteristics to the main study population. The largest 
difference between the overall population and the 
subgroups assessed for safety and QoL was a 9% increase 
in the incidence of patients with performance status 1 in 
the CTCAE safety cohort; all other differences in 
individual characteristics were within 5%.
At the time of the disease-free survival analysis there 
had been 740 events in the 3 month group and 742 events 
in the 6 month group. 3 year disease-free survival was 
76·7% (95% CI 75·1–78·2) in the 3 month group and 
77·1% (75·6–78·6) in the 6 month group, giving an HR 
of 1·006 (0·909–1·114, p=0·012) which met the criteria 
for non-inferiority (figure 2).
3 year overall survival is shown in figure 2. 393 patients 
died in the 3 month group versus 394 in the 6 month 
group. 16 deaths in each group were related to the 
protocol treatment. The appendix contains a breakdown 
of causes of death (p 10) and further details of deaths 
related to protocol treatment (p 11).
In a prespecified sensitivity analysis, we also 
examined the difference between the study groups 
according to the actual duration of treatment on the 
two randomised groups (appendix p 1). None of these 
analyses showed non-inferiority. For eligible patients 
who received the actual assigned study duration of 
3 and 6 months, the observed HR was 1·158 (95% CI 
1·018–1·317, p=0·641).
Forest plots by stratification factors and randomisation 
timepoint are shown in figure 3. The most marked 
heterogeneity was for the dependence of the duration 
effect on the initial choice of regimen (p=0·069), so we 
did a post-hoc analysis of disease-free survival for the 
two durations of therapy for CAPOX and FOLFOX 
regimens (figure 4). For those patients receiving CAPOX 
the test for non-inferiority in this post-hoc analysis was 
statistically significant (p=0·0020). 
Among patients with available chemotherapy duration 
data, 2521 (83%) of 3024 of patients assigned to 3 months 
of treatment actually received 3 months of treatment, 
including 845 (86%) of 980 receiving FOLFOX and 
1676 (82%) of the 2044 receiving CAPOX. 1773 (59%) of 
3013 patients assigned to receive 6 months of treatment 
actually received 6 months of treatment, which was 
similar for those receiving FOLFOX (585 [59%] of 985) 
and CAPOX (1188 [59%] of 2028). 209 (7%) of 
3013 patients assigned to receive 6 months of treatment 
stopped treatment at 3 months. Overall, 842 (14%) of 
6037 patients stopped treatment before 3 months and 
this was roughly evenly split between those assigned to 
receive 3 months (425 [14%] of 3024) and 6 months 
(417 [14%] of 3013) of treatment.
244 patients in the 3 month group and 576 patients in 
the 6 month group cited adverse events as the reason for 
stopping treatment early. The most commonly cited 
individual adverse event causing treatment to be stopped 
in the 3 month group was diarrhoea (90 patients). In the 
6 month group, both diarrhoea (150 patients) and 
peripheral neuropathy (156 patients) were commonly 
cited as reasons for stopping.
Figure 5 shows the dose delivery for fluoropyrimidine 
and oxaliplatin. The median percentage of full fluoro-
pyrimidine dose delivered was 95·3% (IQR 83·1–99·8) 
in the 3 month group and 83·2% (56·7–95·7) in the 
6 month group. The corresponding figures for 
oxaliplatin dose delivery were 96·6% (82·3–99·7) in the 
3 month group and 70·2% (44·3–87·1) in the 6 month 
Figure 3: Disease-free survival and heterogeneity in subgroups by minimisation variables
Categories are listed as recorded at randomisation; ten patients in the 3 month group and 15 patients in the 
6 month group could not be allocated to high risk stage II or stage III based on T/N data recorded at randomisation. 
*These estimates differ slightly because the underlying multivariable Cox model on which they are based includes 
parameters for other minimisation variables, as well as those factors relating to stage; the increased flexibility in 
the expanded stage model allows the influence of these parameters on the high risk stage II estimates to modify. 
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group. These figures were similar irrespective of the 
fluoropyrimidine backbone. The number of patients who 
had recorded fluorouracil or prescribed capecitabine 
dose reductions in the 3 month group were 788 (26%) of 
3009 compared with 1286 (43%) of 3013 in the 6 month 
group. For oxaliplatin, the corresponding figures were 
906 (30%) of 3009 and 1869 (62%) of 3013.
Given previous trial data,20 it is known that there is a 
marked difference in risk of relapse between patients 
with N1 colorectal cancer compared with those with N2 
pathology, so we did a post-hoc analysis comparing T1–3, 
N1 colorectal cancer against T4 and N2 pathology 
(figure 6), and analysed these different prognostic groups 
according to the chemotherapy regimen they received 
(FOLFOX or CAPOX; appendix p 5). For those patients 
with T1-3/N1 disease the test for non-inferiority in this 
post-hoc analysis was statistically significant (p=0·012).
Safety was assessed by the investigators in 868 patients, 
434 (50%) in each group. Sensory neuropathy, diarrhoea, 
neutropenia, fatigue, pain, nausea, and hand-foot 
syndrome were the most common grade 3–5 adverse 
events (table 2). The frequency of grade 3–5 diarrhoea 
(p=0·033), neutropenia (p=0·031), pain (p=0·014), 
hand-foot syndrome (p=0·031), and sensory neuropathy 
(p<0·0001) was significantly higher in the 6 month group 
than in the 3 month group. Diarrhoea and hand-foot 
syndrome were more frequent in patients receiving 
CAPOX and neutropenia was more frequent in patients 
receiving FOLFOX (appendix p 5). The only side-effect 
for which the percentage of patients with adverse events 
Figure 4: Disease-free survival by study group and selected adjuvant regimen
HR=hazard ratio.
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of grade 2 or worse differed by more than 10% between 
the two treatment groups was sensory neuropathy 
(237 [58%] of 409 patients with data in the 6 month group 
vs 103 [25%] of 420 patients with data in the 3 month 
group). Overall, grade 3–5 adverse events were reported 
by 150 (36%) of 420 patients in the 3 month group and 
243 (59%) of 409 patients in the 6 month group 
(p<0·0001). Serious adverse reactions to treatment were 
recorded for all patients who started study treatment. In 
the 3 month group, 421 patients had serious adverse 
reactions (492 individual reports) compared with 
511 patients (606 individual reports) in the 6 month 
group. A breakdown of serious adverse reactions by body 
system is shown in the appendix (p 12). Gastrointestinal 
serious adverse reactions were the most common and 
occurred at similar frequencies in both groups. Adverse 
events of grade 3 or worse with an overall frequency less 
than 10% are shown in the appendix (p 13).
In addition to the assessment using the CTCAE during 
treatment, peripheral neuropathy was also assessed 
using a patient recorded outcome FACT/GOG-Ntx4 
questionnaire. FACT/GOG-Ntx4 data were available from 
2871 patients. We compared the results from the 
FACT/GOG-Ntx4 questionnaire for patients receiving 
3 months of chemotherapy with those receiving 6 months 
of chemotherapy (figure 7). The neuropathy standardised 
adjusted AUC differed significantly between the two study 
groups (p<0·0001), with clear differences appearing at 
month 4 and persisting until at least 5 years (p<0·0001). 
Peak neuropathy occurred at 9 months in the 6 month 
group and at 6 months in the 3 month group.
1829 patients provided data for EORTC QLQ-C30 and 
QLQ-CR29. All the functional and symptom scales 
in EORTC QLQ-C30 showed significant differences 
favouring the 3 month group (ie, fewer side-effects and 
better function) in terms of standardised adjusted AUC 
(p<0·0001 for all functional scales adjusted for multiple 
testing; appendix p 15). For the EORTC QLQ-CR29 
questionnaire, significant differences were detected in 
the body image (p=0·037), dry mouth (p<0·0001), hair 
loss (p=0·035), and taste scales (p<0·0001; all p values 
adjusted for multiple testing; appendix p 15).
The global health status and the functional and 
symptom scales that significantly differed between the 
groups matched each other during the first 3 months of 
treatment, then separated between months 3 to 6 as 
function improved or symptoms decreased in patients 
who had stopped treatment at 3 months (appendix pp 2, 
15). The maximum difference in means was generally 
seen at 6 months and, in accordance with the categories 
of Osoba and colleagues,13 these mean differences in 
functional and global health status scales represented 
“moderate” changes (values between 10–20) for global 
health status, role functioning, and social function and “a 
little” change (values between 5–10) for physical 
functioning, emotional functioning, and cognitive 
functioning. Thereafter, the mean values converged 
during months 9 and 12 after patients in the 6 month 
group had stopped treatment. The largest difference in 
means at 12 months was 3·79 (SE 1·06) for role 
Figure 5: Treatment delivery by selected adjuvant regimen
Box and whisker plots indicate median and IQR (boxes) and range (whiskers). Dots represent outliers.
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functioning (appendix p 15). The graph for global health 
status is shown in the appendix (p 2).
1828 patients provided data for EQ-5D-3L. The stand-
ardised adjusted AUCs differed significantly for both the 
EQ-5D self-rated visual analogue scale (p=0·00081) and the 
EQ-5D-3L health index (p=0·00081; appendix p 15). 
Plotting the EQ-5D scales showed that the differences 
between the two groups of the study were restricted to 
months 4, 5, and 6, the period when patients in the 
6 month group were still receiving treatment and those in 
the 3 month group had stopped. The maximum difference 
in means was at 6 months and these differences were 
consistent with clinically important differences (appendix 
p 15).21 This pattern was also noticeable for the EQ-5D self-
rated visual analogue scale; patients in the 6 month group 
had significantly lower QoL than those in the 3 month 
group during months 4, 5, and 6, but after this point, there 
were no overall clinically important differences up to the 
6 year follow-up (appendix p 3).
To investigate the potential effects of missing data 
on the results from the FACT/GOG-Ntx4, EORTC, 
and EQ-5D assessments, the reasons for missing 
questionnaires were recorded (appendix p 16). The 
reasons were broadly similar between the groups and 
were mainly related to errors of various kinds. Similarly, 
an analysis of missingness according to baseline 
factors indicated that the patients who completed the 
questionnaires were representative of the patients who 
participated in this aspect of the study, with any 
associations between a questionnaire being missing and 
Figure 6: Disease-free survival by study group and stage III risk group
HR=hazard ratio.
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baseline characteristics being small (appendix p 17). 
Finally, we did a sensitivity analysis to compare the 
primary imputed results with the results based on 
observed data only or the imputed results for patients 
who completed baseline questionnaires only. The results 
of these analyses were all very similar to the findings of 
the main study (appendix p 18).
We did an exploratory analysis to examine the differences 
in QoL scales between patients whose worst responses to 
the questions on the GOGNtx4 questionnaire about 
whether they had numbness, tingling, or discomfort in 
their hands or feet were “Quite a bit” or “Very much” and 
those whose worst responses were “Somewhat“, “A little 
bit”, or “Not at all” (appendix p 4). This analysis identified 
statistically and clinically significant poorer QoL between 
these patient groups at 1 year, 3 years, and 5 years, apart 
from EQ-5D visual analogue scale at 1 year, for which the 
difference was not clinically significant. The proportion of 
patients recording neuropathy symptoms as being present 
“Quite a bit” or “Very much” was significantly higher in the 
6 month group than in the 3 month group at each timepoint 
(248 [34%] of 721 vs 99 [14%] of 721, p<0·0001 at 1 year; 
63 [32%] of 199 vs 30 [15%] of 198, p<0·0001 at 3 years; 
49 [29%] of 170 vs 30 [16%] of 193, p=0·0032 at 5 years).
Discussion
Our results show the non-inferiority of 3 months of 
adjuvant oxaliplatin-containing chemotherapy treatment 
compared with 6 months of treatment for patients with 
high-risk stage II and stage III cancer of the colon and 
rectum. The shorter treatment duration was also 
associated with reduced toxicity and less deterioration in 
QoL. Because this study recruited 6088 patients with 
conventionally defined high-risk stage II and stage III 
colorectal cancer from a large number of centres and 
countries and made use of standard chemotherapy 
regimens, the study findings are applicable to a typical 
patient with colorectal cancer needing adjuvant 
chemotherapy treatment. The non-inferiority boundary 
was set to exclude a maximum 2·5% fall in 3 year 
disease-free survival in patients in the 3 month group 
compared with those in the 6 month group, which—as 
estimated on the basis of results from previous trials—
would yield a predicted 3 year disease-free survival of 
78%. This threshold of 2·5% was chosen because it was 
half the difference seen in 3 year disease-free survival 
between patients in the oxaliplatin-containing group and 
those in the fluoropyrimidine only group in the MOSAIC 
study. It was felt by clinicians commonly treating 
Figure 7: Peripheral neuropathy by study group
Patients reported peripheral neuropathy with the GOG Ntx4 questionnaire. Although results were available beyond year 6, they have been omitted because of small numbers and resultant wide confidence 
intervals. Error bars show 95% CIs. *The low completion rates at these timepoints reflect the fact that, initially, neurotoxicity data were only collected up to 12 months and there was a delay before an 
amendment extended the collection to the whole study period. †Low return rate because patients were assessed at the start of last cycle rather than 6 months (which corresponds to end of cycle).
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colorectal cancer that this small difference would be an 
acceptable payoff to bring about a significant reduction 
in long-term neuropathy and potential improvement in 
QoL to patients who achieve a long-term cure. This 
difference corresponds to an HR of 1·13, which we aimed 
to detect with 90% power at the 2·5% one-sided level of 
statistical significance.
Because 6088 patients were recruited and 1482 events 
were recorded (rather than our initial target of 
9500 patients with 2750 events), the power was reduced to 
66%. However, we were still able to show the non-
inferiority of 3 months of treatment compared with 
6 months of treatment (p=0·012) across the trial 
population as a whole (stage III and high risk stage II 
disease; colon and rectal cancer), with 3 year disease-free 
survival of 77·1% (95% CI 75·6 to 78·6) for patients in the 
6 month group and 76·7% (75·1 to 78·2) for those in the 
3 month group (HR 1·006, 0·909 to 1·114). The absolute 
loss in 3 year disease-free survival with 3 months of 
treatment was 0·4% (–1·8 to 2·6). Patients in the 6 month 
group had similar 3 year disease-free survival to that seen 
with 6 months of oxaliplatin-containing adjuvant 
chemotherapy in the MOSAIC study (78·2%) and NSABP 
C07 studies (76·1%), suggesting that the outcome 
observed in our control group was similar to that 
previously seen.3,4 However, it is important to note that in 
the SCOT trial, only 1096 (18%) of 6088 patients had high-
risk stage II disease, whereas in MOSAIC and NSABP-C07, 
40% and 30% of patients had all-risk stage II disease. Our 
definition of high risk-stage II disease was the same as 
that used in MOSAIC. At the time SCOT was initiated, 
less data were available on adjuvant chemotherapy for 
rectal cancer because many adjuvant studies have excluded 
these patients, and patients with rectal cancer were eligible 
to participate if they had received no preoperative 
chemotherapy (short-course radiotherapy alone was 
allowed) and had undergone total mesorectal excision 
with an R0 resection. The only adjuvant chemotherapy 
these patients received was within this study and 
randomised for the duration of treatment.
We did comparisons of disease-free survival based on 
the actual duration of treatment received in the study 
groups, as well as the primary intention-to-treat analyses. 
These subanalyses did not show non-inferiority, but are 
inherently biased by the differential exclusion of patients 
not able to receive prolonged therapy because of the 
different target treatment durations in the study groups. 
In a setting such as this where differential compliance is 
intrinsic to the treatments being compared, our view is 
that the intention-to-treat analysis is a more accurate 
reflection of the impact of the intervention on actual 
clinical practice.
In terms of our analyses of smaller subgroups, we have 
not been able to draw solid conclusions about the effect of 
treatment duration on specific patient populations such 
as those with high-risk stage II disease or patients with 
rectal cancer because the numbers in these subgroups 
were relatively small and few events occurred. However, 
the Forest plots did not show any differences in the effect 
of the duration of adjuvant chemotherapy between 
patients with high-risk stage 2 disease and those with 
stage III disease and between those with rectal cancer and 
those with colon cancer. Therefore, there is no reason to 
consider that these subpopulations should be treated 
differently in clinical practice to the trial population as a 
whole. We can only apply the SCOT results to patients 
being considered for doublet chemotherapy as tested 
within the study. In clinical practice in many parts of the 
world, a substantial proportion of patients with high-risk 
stage II disease or stage III disease (especially if older 
than 70 years of age) receive only single-agent 
fluoropyrimidine for 6 months because the addition of 
oxaliplatin to fluoropyrimidine has not been shown to 
improve survival in these patients.22
Other factors to consider in terms of prognosis and 
prediction of response to treatment include the sidedness 
of the cancer (right vs left), RAS and BRAF status, which 
affect prognosis in metastatic disease, and microsatellite 
instability status, which affects the outcome of adjuvant 
treatment.23 These questions cannot yet be answered by 
the results of SCOT, but there is a translational research 
substudy—the TransSCOT study, which is ongoing—
that will look at these factors.
It is more difficult to give 6 months of treatment than 
3 months of treatment. In the SCOT study, 2521 (83%) 
of 3024 patients assigned to 3 months received 
3 months of treatment, whereas only 1773 (59%) of 
3013 patients assigned to 6 months received 6 months 
of treatment. However, the median percentage of the 
full expected dose of fluoropyrimidine received varied 
between 94% and 98% for the 3 month group and 82% 
and 85% for the 6 month group, depending on regimen 
choice. The corresponding figures for oxaliplatin were 
between 96% and 98% for the 3 month group and 69% 
and 73% for the 6 month group. Given that the median 
fluoropyrimidine and oxaliplatin doses received were 
similar between the two regimens (figure 5), compliance 
to treatment is unlikely to explain the difference seen 
between the two regimens.
Our results showed that 6 months of adjuvant 
chemotherapy was significantly more toxic than 3 months 
of treatment. This difference was most marked for 
peripheral neuropathy, with 237 (58%) of 409 patients in 
the 6 month group reporting grade 2 or worse neuropathy 
compared with 103 (25%) of 420 patients in the 3 month 
group. Peripheral neuropathy, as reported via a patient 
questionnaire, was significantly worse in the 6 month 
group and persisted for at least 5 years (figure 7). 
Other adverse events that are symptomatically important 
to patients such as diarrhoea and hand-foot syndrome 
were also significantly more common with 6 months of 
treatment. We do note that our conclusions regarding 
long-term neuropathy must been seen in light of the 
substantial proportion of missing data. However, the 
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effects are large, as are the significance levels, and there 
is no evidence that these comparisons are biased between 
the groups,
QoL, as measured by QLQ-C30 global health status and 
EQ-5D-3L, declined while patients were receiving 
chemotherapy. QoL was therefore predictably worse for 
longer in those patients assigned to receive 6 months  of 
treatment compared with 3 months of treatment. 
QoL improved after treatment stopped and by 1 year, 
there were no clinically important differences between 
the two study groups.
It is now realised that clinician assessment of 
neuropathy with methods such as the CTCAE are less 
sensitive than patient-reported outcomes such as 
FACT/GOG-Ntx4 and EORTC QLQ chemotherapy-
induced peripheral neuropathy (CIPN) 20.24 In this study, 
although QoL seemed to recover by 1 year, chronic 
sensory peripheral neuropathy persisted for up to 5 years. 
We found a significant difference in peripheral 
neuropathy, with more patients in the 6 month group 
reporting “Quite a bit“ or “Very much” numbness, 
tingling, or discomfort in their hands or feet in the 
FACT/GOG-Ntx4 questionnaire, which correlated with 
significantly worse QoL at 1 year, 3 years, and 5 years. 
These differences in QoL were at least minimally clinically 
important (apart from the result for EQ-5D visual 
analogue scale at 1 year). This observation is similar to 
one made in a study showing a correlation between those 
patients with the most neuropathy symptoms (worst 10%) 
measured by EORTC QLQ CIPN 20 and a reduction in 
QoL measured by QLQ-C30 between 2 years and 11 years 
after treatment for colorectal cancer with oxaliplatin.25 
The absence of an overall difference in QoL seems to 
obscure a meaningful difference in the group of patients 
who have the worst long-term chronic neuropathy.
In a parallel initiative to SCOT, the IDEA collaboration 
was set up to consolidate the results from all trials 
worldwide that were attempting to answer this question 
of adjuvant chemotherapy duration, particularly for 
stage III colon cancer (ie, SCOT, TOSCA, IDEA France, 
CALGB/SWOG 80702, ACHIEVE, and HORG).26 Our 
results, like those from the IDEA collaboration27 suggest 
that the relative effect of shortening the duration of 
adjuvant chemotherapy might depend on the initial 
choice of chemotherapy regimen (CAPOX vs FOLFOX; 
p=0·069 for heterogeneity in SCOT). When we looked at 
the effect of duration for each regimen separately, 
CAPOX showed non-inferiority in terms of disease-free 
survival for 3 months versus 6 months of treatment, but 
this was not the case for patients receiving FOLFOX. 
The reasons for this difference are not clear. The choice 
of chemotherapy regimen was not randomised but 
instead chosen by the physician and patient and the 
reasons why specific regimens were chosen for individual 
patients are not known.
Also important to note for capecitabine, an oral drug 
that is self-administered at home, is that we only know 
the prescribed dose and do not have detailed compliance 
data, meaning that we might overestimate the 
fluoropyrimidine dose intensity for patients receiving 
CAPOX. However, in our experience, except in instances 
where clinicians curtail or modify doses according to 
intracycle toxicity, compliance with oral chemotherapy 
drugs is high.
Since the difference in the impact of treatment duration 
between the CAPOX and FOLFOX regimens does not 
seem to be easily explained by compliance with treatment 
or differences in the overall percentage of standard drug 
doses that were delivered, we perhaps need to consider 
other potential reasons for this finding. In the CAPOX 
regimen, the dose of oxaliplatin given with each cycle is 
higher than that given in FOLFOX, and therefore we 
presume that higher peak doses of oxaliplatin are 
achieved. Additionally, although the peak dose of 
fluoropyrimidine will be lower with CAPOX (capecitabine 
is given twice daily orally for two out of three weeks) than 
with FOLFOX (where the fluoropyrimidine is given as a 
bolus, then infused over 2 days every 2 weeks), the 
duration and continuity of exposure is greater. Could the 
micrometastatic disease be rendered more sensitive by 
one or both of these differences? If each of the cells in this 
micrometastatic setting are cycling through S phase only 
sporadically, does the continuity of exposure of the 
fluoropyrimidine in the form of capecitabine mean that 
there is a greater overall chance that these cells will be 
exposed to fluoropyrimidine at the critical part of the cell 
cycle, compared with fluorouracil given as bolus, then 
over 2 days every 2 weeks. This notion is supported by 
data from two previous adjuvant studies.10,28 In terms of 
oxaliplatin, a drug that is nearly always given over 2–4 h, 
does the peak concentration have more of an effect than 
the frequency, giving an advantage to the CAPOX 
regimen and less attrition to efficacy when the overall 
duration of therapy is shortened? Additionally, a higher 
dose of oxaliplatin is given in the first 4 weeks of treat-
ment with CAPOX (260 mg/m²) than with FOLFOX 
(170 mg/m²). It is very difficult to prove these speculative 
theories without developing appropriate adjuvant models 
of malignancy, but the results seen will certainly be a 
focus of strong debate over the coming months and years.
Stage III colorectal cancer is a heterogeneous disease 
and data from the IDEA collaboration and from multiple 
adjuvant trials have shown that patients with T1–3, N1 
pathology have much better outcomes than those with 
either T4 or N2 features.27 This has led to the evolution 
of the concept of a high-risk stage III patient population, 
with either T4 or N2 disease, as opposed to the lower 
risk stage III population (T1–3, N1); we might need to 
consider whether patients with high-risk stage III 
disease need to be treated in a slightly different way to 
those with lower risk stage III disease.
Similarly, our results have shown that patients with 
T1–3, N1 disease have a much better 3 year disease-free 
survival than those with either T4 or N2 pathology. 
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We found that, in patients with T1–3, N1 colorectal cancer, 
3 months of treatment was non-inferior to 6 months (HR 
0·908, 95% CI 0·75–1·098). However, for patients with 
T4 or N2 high-risk stage III disease, non-inferiority was 
not met (1·068, 0·934–1·222). The HR for disease-free 
survival is greater than 1 for the 3 months duration 
compared to 6 months, suggesting that there could be 
some small loss of efficacy, but the confidence intervals 
are wide, making this difference difficult to interpret with 
certainty. Notably, the observed absolute deficit in 3 year 
disease-free survival between the 3 months and 6 months 
of treatment for the high-risk group (T4 or N2 disease) is 
1·8%, which has to be balanced against the increased 
toxicity seen with 6 months of treatment. This is 
particularly important because the worsened peripheral 
neuropathy persists for at least 5 years after treatment 
and results in worse QoL outcomes.
For patients with T4 or N2 pathology, the absolute 
increase in 3 year disease-free survival with 6 months 
versus 3 months of treatment was 2·7% (95% CI 
–4·1 to 9·6) for FOLFOX and 1·3% (95% CI –3·7 to 6·2) 
for CAPOX (appendix p 5). However, the forest plots did 
not show a difference in outcome according to duration 
of treatment between N1 and N2 disease. In view of the 
difference in toxicity seen with longer treatment, many 
patients will accept a small reduction in disease-free 
survival in exchange for reduced toxicity and this is 
especially true if they are able to receive CAPOX. There 
is less evidence to support a shorter duration of adjuvant 
treatment if it is decided that the patient needs to receive 
FOLFOX or has T4 disease.
Across the whole trial population, SCOT met the criteria 
for non-inferiority with a difference in 3 year disease-free 
survival of –0·4% (95% CI –2·6 to 1·8) between 3 months 
and 6 months of treatment. While the study was 
underpowered, the 95% CI for the HR lies below the non-
inferiority boundary and the results are consistent with 
those of other individual studies by the IDEA group, 
taking into account how the duration effect depended on 
regimen and risk group. The consistency with these other 
studies indicates that the results of SCOT are unlikely 
to represent a false-positive in terms of showing 
non-inferiority. The concept that underpowered studies 
are more likely to produce false-positives (ignoring the 
factor of publication bias, which does not apply to a large 
scale enterprise such as SCOT) is disputed.29 As noted, 
the results differed with the (non-randomised) choice of 
chemotherapy regimens and we can recom mend a 
3 month duration of adjuvant chemotherapy for patients 
with T1–3, N1 disease (2677 [44%] of the 6088 patients in 
the SCOT study) if the patient is felt to be suitable for the 
CAPOX regimen. We have not been able to show with 
any statistical certainty that 3 months of treatment was 
non-inferior to 6 months for patients receiving FOLFOX, 
for whom there was an absolute increase in 3 year disease-
free survival with 6 months versus 3 months of treatment 
of 2·9% (95% CI –6·7 to 0·8).
Despite the study’s size, there are limitations to the 
reliability of conclusions that can be drawn for some 
subgroups. The choice of FOLFOX and CAPOX 
chemotherapy regimen was not randomised and there 
was clear heterogeneity between the two regimens, the 
reasons for which are unclear. For patients with low-risk 
stage 3 disease receiving CAPOX, 3 months of treatment 
is sufficient, whereas non-inferiority was not shown for 
FOLFOX. High-risk stage III disease includes either T4 or 
N2 disease (or both) and this study has not been able to 
show whether the effect of duration of adjuvant 
chemotherapy is the same for T4 and N2 disease.  The final 
decision on treatment duration and regimen used for 
each individual will depend on a careful discussion 
between the clinician and patient, taking into account the 
risk of recurrence, the likely absolute difference in disease-
free survival and risk of long-term toxicity, and the 
strength of evidence for that particular setting available 
both from SCOT and the wider IDEA analysis.
SCOT is, to our knowledge, the largest single randomised 
study on the adjuvant treatment of colorectal cancer to date. 
The study achieved its primary endpoint of showing that 
3 months of oxaliplatin-containing adjuvant chemotherapy 
is non-inferior to 6 months of the same treatment in the 
overall trial population. 3 months of treatment might 
therefore be considered a new standard of care for adjuvant 
chemotherapy, especially if CAPOX is to be given. 
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